TherapeuticsMD (TXMD) Reports In-Line Q4 EPS

TherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.12), in-line with the analyst estimate of ($0.12). Revenue for the quarter came in at $4.49 million versus the consensus estimate of $5.91 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Equirus Starts JSW Energy Ltd (JSW:IN) at Long (1)
• AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance